The estimated Net Worth of Steven B. Binder is at least $7.93 million dollars as of 27 August 2024. Mr. Binder owns over 5,055 units of Mannkind Corp stock worth over $6,589,909 and over the last 7 years he sold MNKD stock worth over $407,125. In addition, he makes $937,851 as Chief Financial Officer at Mannkind Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Binder MNKD stock SEC Form 4 insiders trading
Steven has made over 14 trades of the Mannkind Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 5,055 units of MNKD stock worth $30,027 on 27 August 2024.
The largest trade he's ever made was selling 47,810 units of Mannkind Corp stock on 22 May 2023 worth over $223,751. On average, Steven trades about 3,284 units every 74 days since 2018. As of 27 August 2024 he still owns at least 1,075,026 units of Mannkind Corp stock.
You can see the complete history of Mr. Binder stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Binder biography
Steven B. Binder CPA serves as Chief Financial Officer of the Company. Before joining MannKind Corporation, Mr. Binder served as Vice President and Chief Financial Officer of the International Group of Stryker Corporation, a medical device and equipment manufacturing company based out of Singapore, since 2013. Prior to Stryker Corporation, Mr. Binder served in a series of senior leadership roles at Bristol-Myers Squibb Company (“BMS”). His last four positions at BMS were Vice President, Finance roles over the following geographic operating units: United States from 2012 to 2013, Europe from 2008 to 2011, Asia Pacific from 2005 to 2007 and Japan from 2003 to 2005. Prior to that, Mr. Binder served in three senior leadership roles for Oncology Therapeutics Network (“OTN”), a U.S.-based independent subsidiary of BMS: Vice President, Strategic Development from 2001 to 2003, Vice President, Customer Operations from 2000 to 2001 and Chief Financial Officer from 1997 to 2000. Before OTN, Mr. Binder completed three finance and accounting roles for BMS Worldwide Medicines Group after joining BMS in 1992. Before BMS, he worked for Deloitte & Touche LLP in a series of auditing roles over an eight year period beginning in 1984. Mr. Binder received a B.S. degree in Accounting and Business Administration from Muhlenberg College and is a Certified Public Accountant.
What is the salary of Steven Binder?
As the Chief Financial Officer of Mannkind Corp, the total compensation of Steven Binder at Mannkind Corp is $937,851. There are 5 executives at Mannkind Corp getting paid more, with Michael Castagna having the highest compensation of $1,551,760.
How old is Steven Binder?
Steven Binder is 57, he's been the Chief Financial Officer of Mannkind Corp since 2017. There are 9 older and 12 younger executives at Mannkind Corp. The oldest executive at Mannkind Corp is Kent Kresa, 82, who is the Independent Chairman of the Board.
What's Steven Binder's mailing address?
Steven's mailing address filed with the SEC is 1, Casper Street, Danbury, Fairfield County, Connecticut, 06810, United States.
Insiders trading at Mannkind Corp
Over the last 20 years, insiders at Mannkind Corp have traded over $14,187,027 worth of Mannkind Corp stock and bought 107,212,962 units worth $2,707,661,837 . The most active insiders traders include Alfred E Mann, Juergen Martens et David Thomson. On average, Mannkind Corp executives and independent directors trade stock every 27 days with the average trade being worth of $3,220,647. The most recent stock trade was executed by Stuart A Tross on 3 September 2024, trading 25,000 units of MNKD stock currently worth $156,500.
What does Mannkind Corp do?
mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
What does Mannkind Corp's logo look like?
Complete history of Mr. Binder stock trades at Mannkind Corp
Mannkind Corp executives and stock owners
Mannkind Corp executives and other stock owners filed with the SEC include:
-
Michael Castagna,
Chief Executive Officer, Director -
Dr. Michael E. Castagna Pharm.D.,
CEO & Director -
Stuart Tross,
Chief People and Workplace Officer -
David Thomson,
Executive Vice President, General Counsel, Secretary -
Dr. Michael E. Castagna,
CEO & Director -
Steven Binder,
Chief Financial Officer -
Dr. David B. Thomson,
Exec. VP, Gen. Counsel & Sec. -
Joseph Kocinsky,
Chief Technology Officer -
Steven B. Binder,
Chief Financial Officer -
Joseph Kocinsky M.B.A., M.S.,
Chief Technology Officer -
Dr. Stuart A. Tross,
Chief People & Workplace Officer -
Rosabel Alinaya,
Vice President of Investor Relations, Interim Corporate Controller, Treasurer -
Christine Mundkur,
Independent Director -
Kent Kresa,
Independent Chairman of the Board -
Ronald Consiglio,
Independent Director -
Michael Friedman,
Independent Director -
James Shannon,
Independent Director -
Kevin Kaiserman,
Vice President - Medical Affairs and Safety -
Jennifer Grancio,
Independent Director -
Anthony Hooper,
Independent Director -
Alejandro Galindo M.B.A., M.S.,
Chief Commercial Officer -
James Patrick McCauley Jr., J.D., M.B.A.,
Chief Commercial Officer -
John F. Bedard,
Sr. VP of Worldwide Regulatory Affairs -
Rosabel Realica Alinaya,
VP of Investor Relations & Treasury -
Thomas Hofmann M.D., Ph.D.,
Chief Scientific Officer -
Matthew J Pfeffer,
Corporate VP and CFO -
Henry L Nordhoff,
Director -
David Mac Callum,
Director -
Raymond W. Urbanski,
Corp VP, CMO -
David M Kendall,
Chief Medical Officer -
Elizabeth Garrett Ingram,
Chief Marketing Officer -
Courtney Barton,
Chief Compl & Privacy Officer -
Patrick Mc Cauley,
Chief Commercial Officer -
John R. Riesenberger,
VP & Chief Commercial Officer -
Richard L Anderson,
VP & CFO -
Heather Hay Murren,
Director -
Kathleen Connell,
Director -
Llew Keltner,
Director -
Dan Burns,
VP & President, MKBP -
W Wendell Cheatham,
VP, Medical & Reg Affairs -
Juergen Martens,
Corporate VP -
Hakan Edstrom,
President & COO -
Alfred E Mann,
Chairman & CEO -
Diane Palumbo,
Vice President, Human Resource -
Abraham E Cohen,
Director -
Peter C Richardson,
Chief Scientific Officer -
Lauren M Sabella,
EVP Chief Operating Officer -
Alejandro Galindo,
EVP Endocrine Business Unit -
Burkhard Blank,
EVP Chief Medical Officer -
Sanjay R Singh,
EVP Technical Operations -
Christopher B Prentiss,
Chief Financial Officer -
Sabrina Kay,